Skip to main content

Verified by Psychology Today

Therapy

Revolutionizing Mental Health: Psychedelics and TMS

The transformative impact of cutting-edge therapies on mental health care.

Key points

  • Emerging therapies like psychedelics and TMS revolutionize personalized, effective mental health care.
  • Psychedelic therapy shows promise in treating PTSD, anxiety, and depression with drugs and psychotherapy.
  • Transcranial magnetic stimulation offers noninvasive, FDA-approved treatment for severe depression.

The landscape of mental health treatment is undergoing a significant transformation, driven by groundbreaking research and novel therapeutic interventions. From the revolutionary potential of psychedelic-assisted therapy to the rise of noninvasive treatments like transcranial magnetic stimulation (TMS), these advancements are poised to change how we approach psychological conditions.

Psychedelic-Assisted Therapy: A New Frontier in Mental Health

As our understanding of mental health deepens, psychedelic-assisted therapy (PAT) is gaining traction as a revolutionary approach to treatment. This innovative therapy combines the use of psychedelic drugs with structured psychotherapy to address mental health disorders. Substances like MDMA, ketamine, LSD, cannabis, and psilocybin (often referred to as "magic mushrooms") are showing promise in treating conditions such as PTSD, anxiety, and depression.

The Historical Context and Resurgence of Psychedelics

Psychedelic substances have a long history of use in various cultural and spiritual contexts, dating back thousands of years. Indigenous peoples across the Americas, Africa, and Asia have utilized these substances for ceremonial and healing purposes. However, the Western world’s relationship with psychedelics took a dramatic turn in the mid-20th century.

During the 1950s and 1960s, psychedelics like LSD and psilocybin were subjects of significant scientific research, with promising results in treating mental health conditions. However, the cultural and political backlash against the countercultural movement led to the criminalization of these substances and a subsequent halt in research. This “psychedelic dark age” persisted for decades, stalling progress until the early 2000s, when a new wave of studies began to explore the therapeutic potential of these drugs under strict clinical conditions.

The resurgence of interest in psychedelics is fueled by a growing body of evidence supporting their safety and efficacy when administered in controlled environments. The modern approach to psychedelic therapy is vastly different from the unregulated use that characterized the 1960s. Today, clinical trials are meticulously designed, with rigorous protocols to ensure patient safety and maximize therapeutic benefits.

The Promise and Risks of Psychedelic-Assisted Therapy

While the potential of PAT is compelling, it is essential to recognize and mitigate the associated risks:

  • Psychological Risks: Patients may experience "bad trips," characterized by extreme fear, paranoia, or emotional overload. A study published in Frontiers in Psychology noted that while most participants in psychedelic therapy report positive experiences, about 7.6 percent of users had severe psychological distress during their sessions. Psychedelics can also trigger psychotic episodes in predisposed individuals and may bring repressed memories to the surface, causing acute emotional distress.
  • Physiological Risks: Psychedelics like MDMA, LSD, and psilocybin are known to increase heart rate and blood pressure, posing risks for individuals with cardiovascular conditions. A clinical review published in The Lancet Psychiatry highlighted the importance of medical screening to minimize these risks during PAT sessions. Drug interactions, particularly with SSRIs, can lead to dangerous side effects.
  • Potential for Abuse and Ethical Concerns: The euphoric states induced by psychedelics carry a high potential for abuse if not strictly monitored in a clinical setting. Ethical concerns also arise around dependency, informed consent, and careful patient monitoring. Ethical frameworks for psychedelic therapy, as discussed in The Journal of Clinical Psychiatry, emphasize the need for clear guidelines to manage these risks.

Despite these risks, the controlled environment of clinical trials, along with the presence of trained therapists, significantly reduces the likelihood of adverse outcomes. The therapeutic potential of psychedelics is being unlocked in a way that is both scientifically rigorous and ethically sound, paving the way for their integration into mainstream mental health care.

The Future of Psychedelic-Assisted Therapy

Research into psychedelic-assisted therapy is yielding exciting results, particularly in areas where traditional treatments have failed:

  • PTSD: Both ketamine-assisted and MDMA-assisted therapies have shown prolonged symptom reduction in PTSD patients. A study published in The Journal of Psychopharmacology reported that 67 percent of patients treated with MDMA-assisted therapy no longer met the criteria for PTSD one year after treatment. MDMA, in particular, reduces activity in the amygdala (the brain's "fear center") and enhances empathy, trust, and openness, making it especially beneficial for PTSD treatment.
  • Depression and Anxiety: Psilocybin and ketamine-assisted therapies have shown significant promise in treating treatment-resistant depression and anxiety, especially when traditional medications and cognitive therapy have failed. A 2021 study in JAMA Psychiatry found that 71 percent of participants experienced significant reductions in depression symptoms after a single psilocybin session. The profound effects of these therapies are believed to stem from their ability to promote neural plasticity, allowing patients to break free from entrenched patterns of negative thinking and behavior.
  • Substance Use Disorders: Early clinical trials suggest that psychedelics like psilocybin may help individuals overcome addiction by reducing cravings and enhancing psychological flexibility. Research published in The Journal of Psychopharmacology found that psilocybin-assisted therapy led to significant reductions in alcohol misuse among participants with alcohol dependence. The potential for psychedelics to treat a range of addictions, including alcohol, nicotine, and opioids, is one of the most promising avenues of current research.

The integration of psychedelic-assisted therapy into mainstream mental health care is not without its challenges. Regulatory hurdles, public perception, and the need for widespread education about the safe and effective use of these therapies are significant barriers that must be overcome. However, the progress made in recent years suggests that psychedelics could become a cornerstone of mental health treatment in the not-too-distant future.

The Rise of Noninvasive Treatments: Transcranial Magnetic Stimulation (TMS)

Complementing these innovations is the emergence of noninvasive treatments like transcranial magnetic stimulation (TMS), which offers new hope for individuals with treatment-resistant depression.

How TMS Works and Its Impact on Depression

TMS is a brain stimulation technique that targets central nervous system activity through magnetic fields, inducing electrical currents that can normalize brain activity and shift mood and cognition. Recently, the FDA approved accelerated TMS, also known as the Stanford neuromodulation therapy (SNT) protocol, for depression. This protocol involves five days of treatment with 10 daily sessions, offering rapid relief for those with severe depression. A study published in The American Journal of Psychiatry showed that 80 percent of patients with severe depression experienced significant symptom relief after undergoing the SNT protocol.

Expanding the Use of TMS Beyond Depression

While TMS is primarily known for its efficacy in treating major depressive disorder, research is expanding its application to other mental health conditions. Studies are currently exploring the use of TMS in treating conditions such as anxiety disorders, obsessive-compulsive disorder (OCD), and post-traumatic stress disorder (PTSD). The versatility of TMS lies in its ability to target specific brain regions, allowing for tailored treatments that address the unique neural patterns associated with different conditions.

One promising area of research is the use of TMS in combination with other therapeutic modalities, such as cognitive behavioral therapy (CBT). Preliminary studies suggest that combining TMS with CBT can enhance the efficacy of both treatments, leading to more durable and comprehensive outcomes for patients. This multimodal approach represents a new frontier in mental health care, where personalized treatment plans can be developed based on an individual’s specific needs and neurological profile.

Conclusion: The Future of Mental Health Is Here

The intersection of cutting-edge research and practical application in psychology leads us into an exciting new era. Through innovative therapies like psychedelic-assisted therapy and noninvasive treatments such as TMS, the future of mental health care is becoming more personalized and effective.

Rapid advancements in mental health treatments hold great promise for addressing some of the most challenging conditions facing individuals. As research continues to evolve, the hope is that these therapies will become more widely accessible, providing relief to those who have struggled with mental illness for years.

To find a therapist, visit the Psychology Today Therapy Directory.

References

Carhart-Harris, R. L., & Goodwin, G. M. (2017). The therapeutic potential of psychedelic drugs: Past, present, and future. Frontiers in Psychology, 8, 174.

Rucker, J. J., Iliff, J., & Nutt, D. J. (2018). Psychiatry & the psychedelic drugs. The Lancet Psychiatry, 5(5), 382-390.

Johnson, M. W., Richards, W. A., & Griffiths, R. R. (2008). Human hallucinogen research: guidelines for safety. The Journal of Clinical Psychiatry, 69(9), 1363-1371.

Mithoefer, M. C., Wagner, M. T., Mithoefer, A. T., Jerome, L., & Doblin, R. (2011). The safety and efficacy of ±3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. Journal of Psychopharmacology, 25(4), 439-452.

Davis, A. K., Barrett, F. S., & Griffiths, R. R. (2021). Effects of psilocybin-assisted therapy on major depressive disorder: A randomized clinical trial. JAMA Psychiatry, 78(5), 481-489.

Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P. C., & Strassman, R. J. (2015). Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. Journal of Psychopharmacology, 29(3), 289-299.

Cole, E. J., Stimpson, K. H., Bentzley, B. S., et al. (2020). Stanford Neuromodulation Therapy (SNT): A double-blind randomized controlled trial. The American Journal of Psychiatry, 177(8), 716-726.

advertisement
More from Cara Gardenswartz Ph.D.
More from Psychology Today